Victoria Chester - Taro Pharmaceutical Vice President - Head of Quality
| TARODelisted Stock | USD 42.97 0.00 0.00% |
Insider
Victoria Chester is Vice President - Head of Quality of Taro Pharmaceutical Industries since 2021.
| Age | 55 |
| Tenure | 3 years |
| Phone | 972 4 847 5700 |
| Web | https://www.taro.com |
Taro Pharmaceutical Management Efficiency
Taro Pharmaceutical's management efficiency ratios could be used to measure how well Taro Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities.Taro Pharmaceutical Industries currently holds 369.06 M in liabilities with Debt to Equity (D/E) ratio of 0.0, which may suggest the company is not taking enough advantage from borrowing. Taro Pharmaceutical has a current ratio of 3.53, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Taro Pharmaceutical's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Kristin Comer | Redhill Biopharma | N/A | |
| BA Esq | Organogenesis Holdings | 55 | |
| MBA MBA | Evotec SE ADR | 54 | |
| Ziping Luo | Amphastar P | 74 | |
| Rob Jackson | Redhill Biopharma | N/A | |
| Philip Terpolilli | Prestige Brand Holdings | N/A | |
| Cord Dohrmann | Evotec SE ADR | 60 | |
| P Yugandhar | Dr Reddys Laboratories | 49 | |
| Christian Dargel | Evotec SE ADR | 53 | |
| K Krishnan | Dr Reddys Laboratories | 61 | |
| Adel Mekhail | Prestige Brand Holdings | 63 | |
| Penny Wan | Dr Reddys Laboratories | N/A | |
| Kurt Matheson | Organogenesis Holdings | N/A | |
| Jacob MBA | Amphastar P | 50 | |
| Scott Sudduth | Collegium Pharmaceutical | N/A | |
| Yongfeng Zhang | Amphastar P | 77 | |
| Zorina Pitkin | Organogenesis Holdings | N/A | |
| Elizabeth JD | ANI Pharmaceuticals | N/A | |
| Alex Dasalla | Collegium Pharmaceutical | N/A | |
| Matthias Evers | Evotec SE ADR | 51 | |
| Brian Grow | Organogenesis Holdings | 47 | |
Management Performance
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 |
Taro Pharmaceutical Leadership Team
Elected by the shareholders, the Taro Pharmaceutical's board of directors comprises two types of representatives: Taro Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Taro. The board's role is to monitor Taro Pharmaceutical's management team and ensure that shareholders' interests are well served. Taro Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Taro Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Erik Zwicker, Vice President General Counsel, Secretary | ||
| Abhay Gandhi, Vice Chairman of the Board | ||
| Avi Avramoff, Global Vice President - Research & Development | ||
| Chantal LeBlanc, Vice President - Head of Quality | ||
| Robert Stein, Independent Director | ||
| Erik JD, General VP | ||
| Jayesh Shah, Head of Procurement | ||
| Itamar Karsenti, Vice President - Head of Operations, Haifa | ||
| James Kedrowski, Director | ||
| Sudhir Valia, Director | ||
| Uday Baldota, Chief Executive Officer, Director | ||
| Dilip Shanghvi, Chairman of the Board | ||
| Richard Glaze, Vice President - Head of Information Technology | ||
| Roman Kaplan, Vice Manager | ||
| William Coote, Vice President Treasurer | ||
| Ori Gutwerg, Vice President - Head of US Generics Rx | ||
| Vikash Agarwal, Vice President - Head of Business Development | ||
| Linda Benshoshan, Independent Director | ||
| Michele Visosky, Vice President - Head of Human Resources | ||
| Ara Aprahamian, Vice President - Sales and Marketing | ||
| Itzik Baruch, Vice Services | ||
| Daphne Huang, Chief Financial Officer, Chief Accounting Officer, Vice President | ||
| Victoria Chester, Vice President - Head of Quality | ||
| Dov Pekelman, Independent Director |
Taro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Taro Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0306 | |||
| Return On Asset | 0.0021 | |||
| Profit Margin | 0.09 % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 735.67 M | |||
| Shares Outstanding | 37.58 M | |||
| Shares Owned By Insiders | 78.48 % | |||
| Shares Owned By Institutions | 13.06 % | |||
| Number Of Shares Shorted | 73.56 K | |||
| Price To Earning | 14.57 X |
Pair Trading with Taro Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Taro Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Taro Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Taro Stock
| 0.89 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.85 | TLK | Telkom Indonesia Tbk | PairCorr |
| 0.83 | HYMTF | Hyundai Motor | PairCorr |
| 0.83 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
| 0.78 | PFE | Pfizer Inc Aggressive Push | PairCorr |
The ability to find closely correlated positions to Taro Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Taro Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Taro Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Taro Pharmaceutical Industries to buy it.
The correlation of Taro Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Taro Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Taro Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Taro Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Other Consideration for investing in Taro Stock
If you are still planning to invest in Taro Pharmaceutical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Taro Pharmaceutical's history and understand the potential risks before investing.
| Transaction History View history of all your transactions and understand their impact on performance | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |